2-(3,4-氯苯基)-吡咯烷 | 298690-82-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 2-(3,4-氯苯基)-吡咯烷
• 中文别名: 2-(3,4-二氯苯基)吡咯烷
• 英文名称: 2-(3,4-dichlorophenyl)pyrrolidine
• 英文别名: 2-(3,4-dichloro-phenyl)-pyrrolidine；2-(3,4-Dichlorphenyl)pyrrolidin
• CAS: 298690-82-1
• 化学式: C₁₀H₁₁Cl₂N
• mdl: MFCD02663509
• 分子量: 216.11
• InChiKey: LTITXVXGJJQFJC-UHFFFAOYSA-N

物化性质

• 沸点：
  299.9±40.0 °C(Predicted)
• 密度：
  1.250±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2-(3,4-氯苯基)-吡咯烷 在 盐酸 、 盐酸羟胺 作用下， 以 水 、 异丙醇 为溶剂， 反应 6.42h， 生成 (2E)-4-[2-(3,4-dichlorophenyl)pyrrolidin-1-yl]butan-2-one oxime
  参考文献：
  名称：

  PYRROLIDINYL-ALKYL-AMIDE DERIVATIVES, THEIR PREPARATION, AND THEIR THERAPEUTIC APPLICATION AS CCR3 RECEPTOR LIGANDS

  摘要：

  本发明涉及式(I)或(IA)的吡咯烷基酰胺衍生物，其中变量如本文所定义，涉及它们的制备以及它们作为CCR3受体配体的治疗用途。

  公开号：

  US20110144104A1

文献信息

• TRK INHIBITION
  申请人：NantBio, Inc.

  公开号：US20180346451A1

  公开（公告）日：2018-12-06

  The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

  本发明涉及使用取代嘧啶衍生物来调节肌球蛋白相关激酶（Trk）家族蛋白激酶，并且使用这些取代嘧啶衍生物来治疗疼痛、炎症、癌症、再狭窄、动脉粥样硬化、牛皮癣、血栓形成、与失髓鞘或脱髓鞘相关的疾病、紊乱、损伤或功能障碍，或与神经生长因子（NGF）受体TrkA异常活动相关的疾病或紊乱。
• PIPERIDINE SULPHONAMIDE DERIVATIVES
  申请人：Knust Henner

  公开号：US20090203736A1

  公开（公告）日：2009-08-13

  The present invention relates to piperidine sulphonamide derivatives of formula wherein Ar 1 , Ar 2 , R 1 , R 2 , m and n are as defined in the description and claims, or pharmaceutically suitable acid addition salts thereof. The compounds of formula I are orexin receptor antagonists and the related compounds can be useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag syndrome, circadian rhythms disorder or sleep disorders associated with neurological diseases.

  本发明涉及式(I)的哌啶磺酰胺衍生物，其中Ar1、Ar2、R1、R2、m和n如描述和权利要求中所定义，或其药学上适宜的酸加盐。式(I)的化合物是促进睡眠的受体拮抗剂，相关的化合物可用于治疗睡眠呼吸暂停、嗜睡症、失眠、睡眠障碍、时差综合症、昼夜节律紊乱或与神经系统疾病相关的睡眠障碍。
• Pyrrolidinyl-alkyl-amide derivatives, their preparation, and their therapeutic application as CCR3 receptor ligands
  申请人：Behr Agnes

  公开号：US08420636B2

  公开（公告）日：2013-04-16

  The present invention relates to pyrrolidinyl-alkyl-amide derivatives of formula (I) or (IA) wherein the variables are as defined herein, to their preparation and to their therapeutic use as CCR3 receptor ligands.

  本发明涉及公式（I）或（IA）中的吡咯烷基酰胺衍生物，其中变量如本文所定义，以及它们的制备方法和它们作为CCR3受体配体的治疗用途。
• Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors
  申请人：AMEGEN INC.

  公开号：US20160214971A1

  公开（公告）日：2016-07-28

  The present invention provides compounds of Formula (Ia), and pharmaceutically acceptable salts thereof. The compounds are useful as inhibitors of voltage-gated sodium channels, in particular Nav 1.7. as described in the specification. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention, as well as intermediates and processes useful for making the compounds.

  本发明提供了公式（Ia）的化合物及其药学上可接受的盐。这些化合物可用作电压门控钠通道的抑制剂，特别是Nav 1.7，如规范中所述。这些化合物可用于治疗可通过抑制钠通道治疗的疾病，例如疼痛障碍。还提供了含有本发明化合物的制药组合物，以及制造这些化合物的中间体和工艺。
• Trk inhibition
  申请人：NantBio, Inc.

  公开号：US10738033B2

  公开（公告）日：2020-08-11

  The present invention relates to the use of substituted pyrimidine derivatives to modulate tropomyosin-related kinase (Trk) family protein kinase, and the use of the substituted pyrimidine derivatives for the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA. The present invention also provides compounds of the formula: as defined herein.

  本发明涉及使用取代的嘧啶衍生物来调节肌球蛋白相关激酶（Trk）家族蛋白激酶，以及使用取代的嘧啶衍生物来治疗疼痛、炎症、癌症、再狭窄、动脉粥样硬化、银屑病、血栓形成、与髓鞘脱落或脱髓鞘有关的疾病、失调、损伤或功能障碍，或与髓鞘异常活动有关的疾病或失调、 再狭窄、动脉粥样硬化、牛皮癣、血栓形成、与髓鞘脱落或脱髓鞘有关的疾病、紊乱、损伤或功能障碍，或与神经生长因子（NGF）受体 TrkA 的异常活动有关的疾病或紊乱。 本发明还提供了如本文所定义的式化合物。